Enlivex Therapeutics Files 6-K with Financials
Ticker: ENLV · Form: 6-K · Filed: Nov 14, 2025 · CIK: 1596812
Sentiment: neutral
Topics: financials, sec-filing, foreign-private-issuer
Related Tickers: ENLV
TL;DR
Enlivex Therapeutics (ENLV) dropped its Q3 2025 financials via 6-K, check it out.
AI Summary
Enlivex Therapeutics Ltd. filed a Form 6-K on November 14, 2025, reporting its unaudited condensed consolidated financial statements as of and for the period ending November 14, 2025. The company, formerly known as Bioblast Pharma Ltd., is incorporated in Israel and its principal executive offices are located in Nes Ziona, Israel.
Why It Matters
This filing provides investors with an update on Enlivex Therapeutics' financial position, which is crucial for assessing the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new material events or significant changes.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- November 14, 2025 (date) — Filing Date
- Bioblast Pharma Ltd. (company) — Former Company Name
- Israel (location) — Country of Incorporation and Principal Executive Offices
FAQ
What type of financial statements are included in this 6-K filing?
The filing includes unaudited condensed consolidated financial statements.
When was Enlivex Therapeutics Ltd. formerly known as?
Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd.
Where are Enlivex Therapeutics Ltd.'s principal executive offices located?
The principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel.
Under which act is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Does Enlivex Therapeutics Ltd. file annual reports under Form 20-F or 40-F?
Enlivex Therapeutics Ltd. files annual reports under Form 20-F.
Filing Stats: 309 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2025-11-14 16:30:35
Filing Documents
- ea0265573-6k_enlivex.htm (6-K) — 11KB
- ea026557301ex99-1_enlivex.htm (EX-99.1) — 307KB
- ea026557301ex99-2_enlivex.htm (EX-99.2) — 80KB
- 0001213900-25-110920.txt ( ) — 399KB
Financial Statements
Financial Statements The unaudited condensed consolidated financial of and for the three and nine month periods ended September 30, 2025 and 2024, and the Operating and Financial Review and Prospects of Enlivex for the corresponding periods are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K and incorporated by reference into Enlivex’s registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799 , File No. 333-232413 , File No. 333-232009 , File No. 333-252926 and File No. 333-286956 ), filed with the Securities and Exchange Commission. Exhibit No. 99.1 Unaudited condensed consolidated financial statements for Enlivex as of September 30, 2025 and December 31, 2024 and for the three and nine month periods ended September 30, 2025 and 2024. 99.2 Operating and Financial Review and Prospects as of and for the three and nine month periods ended September 30, 2025 and 2024. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: November 14, 2025 2